Literature DB >> 20385483

Osteosarcoma: time to move on?

Stefan S Bielack.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20385483     DOI： 10.1016/j.ejca.2010.03.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  8 in total

1.  Inhibition of NADPH oxidase 2 induces apoptosis in osteosarcoma: The role of reactive oxygen species in cell proliferation.

Authors:  Kazumasa Kitamoto; Yuji Miura; Sivasundaram Karnan; Akinobu Ota; Hiroyuki Konishi; Yoshitaka Hosokawa; Keiji Sato
Journal:  Oncol Lett       Date:  2018-03-19       Impact factor: 2.967

Review 2.  Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

Authors:  Daniel M Green; Larry E Kun; Katherine K Matthay; Anna T Meadows; William H Meyer; Paul A Meyers; Sheri L Spunt; Leslie L Robison; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

Review 3.  [Chemotherapeutic concepts for bone sarcomas].

Authors:  L Kager; S Bielack
Journal:  Unfallchirurg       Date:  2014-06       Impact factor: 1.000

4.  Comment on: 'Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?'.

Authors:  S S Bielack
Journal:  Br J Cancer       Date:  2012-06-28       Impact factor: 7.640

Review 5.  Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?

Authors:  J E Davies; S Neidle; D G Taylor
Journal:  Br J Cancer       Date:  2012-01-03       Impact factor: 7.640

6.  Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.

Authors:  Kjetil Berner; Kirsten Sundby Hall; Odd R Monge; Harald Weedon-Fekjær; Olga Zaikova; Øyvind S Bruland
Journal:  Sarcoma       Date:  2015-02-17

7.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.

Authors:  J S Whelan; S S Bielack; N Marina; S Smeland; G Jovic; J M Hook; M Krailo; J Anninga; T Butterfass-Bahloul; T Böhling; G Calaminus; M Capra; C Deffenbaugh; C Dhooge; M Eriksson; A M Flanagan; H Gelderblom; A Goorin; R Gorlick; G Gosheger; R J Grimer; K S Hall; K Helmke; P C W Hogendoorn; G Jundt; L Kager; T Kuehne; C C Lau; G D Letson; J Meyer; P A Meyers; C Morris; H Mottl; H Nadel; R Nagarajan; R L Randall; P Schomberg; R Schwarz; L A Teot; M R Sydes; M Bernstein
Journal:  Ann Oncol       Date:  2014-11-24       Impact factor: 32.976

8.  High CD49f expression is associated with osteosarcoma tumor progression: a study using patient-derived primary cell cultures.

Authors:  Patrice Penfornis; David Z Cai; Michael R Harris; Ryan Walker; David Licini; Joseph D A Fernandes; Griffin Orr; Tejaswi Koganti; Chindo Hicks; Spandana Induru; Mark S Meyer; Rama Khokha; Jennifer Barr; Radhika R Pochampally
Journal:  Cancer Med       Date:  2014-05-07       Impact factor: 4.452
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.